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Abstract
To evaluate in routine hospital practice the clinical response to ertapenem in comparison with other parenteral antibiotics in the treat-
ment of community-acquired pneumonia (CAP), clinical records from patients with severe CAP treated with ertapenem from July 2002
to June 2006 in seven Spanish hospitals were retrospectively reviewed. Patients were classiﬁed according to the Pneumonia Severity
Index (PSI). Each ertapenem-treated patient was matched with two patients in the same hospital treated with other antibiotics, accord-
ing to age (difference £5 years), same PSI class and whether or not resident in a nursing home. Seventy-one patients treated with
ertapenem and 131 matched controls were identiﬁed; 71 of the 202 patients came from nursing homes. A larger (p 0.0002) number of
patients were treated with monotherapy in the ertapenem group. In total, 174 patients (86.1%) belonged to PSI classes IV–V; a higher
(p <0.0001) PSI score was found in patients from nursing homes. The mean age was 80.5 years (75% of patients >76 years). Comorbidi-
ties were present in 193 patients (95.5%). No differences were found in median hospital stay (7 days for ertapenem vs. 10 days for
comparators, p 0.066). A slightly higher clinical response rate was obtained for ertapenem vs. comparators (88.7% vs. 77.1%; p 0.0465;
OR 2.25; 95% CI 0.99–5.12), with signiﬁcant differences in clinical response in patients coming from nursing homes (95.8% ertapenem
vs. 63.8% comparators; p 0.0034) but not in non-institutionalized patients (85.4% ertapenem vs. 84.5% comparators; p 0.929). The
higher clinical response to ertapenem vs. comparators in severe CAP was due to its signiﬁcantly higher efﬁcacy in healthcare-associated
CAP in patients coming from nursing homes.
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Introduction
The incidence of community-acquired pneumonia (CAP) in
Spain ranges from 1.8 to 8.8 cases per 1000 inhabitants [1–3],
with 20–35% of the patients requiring hospital treatment [4].
Whereas the mortality of CAP in domiciliary patients is <1%,
it is 12–14% in hospital-treated patients and 30–40% in
those with bacteraemia [5,6]. Correct empirical choice of
antibiotic treatment and initial therapeutic interventions is
essential in minimizing the morbidity and mortality associated
with this condition [7]. The prevalence of multiresistant bac-
teria in CAP has increased, probably owing to the wide use
of antibiotics in respiratory tract infections, to early discharge
from acute care facilities, to invasive medical services in
nursing homes and rehabilitation facilities, and to the shift of
healthcare from institutional to home-based services [7,8].
Ertapenem in Europe is licensed for diabetic foot, skin and
skin-structure infections, intra-abdominal infections, acute
gynaecological infections and CAP [9]. Its in vitro activity
against respiratory pathogens [10,11], together with the
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pharmacokinetic proﬁle of total and free drug [10,12] and the
consequent adequate pharmacodynamic coverage, suggest its
use in severe CAP, where ceftriaxone is the standard therapy
in many countries. Two CAP clinical trials [13,14] have
been performed using ceftriaxone as standard comparator. In
a pooled analysis of those two trials [15] clinical cure rates
for ertapenem and ceftriaxone were 92.0% and 91.8%,
respectively, in clinically evaluable patients, and clinical cure
rates in the subgroup of patients with isolation of Streptococ-
cus pneumoniae in pre-treatment cultures were also around
90%.
The aim of this study was to assess the efﬁcacy of ertape-
nem in the treatment of CAP in daily practice by retrospec-
tively reviewing data from patients admitted to hospital with
a diagnosis of CAP and treated with ertapenem in a 4-year
period after the introduction of ertapenem in Spain.
Materials and Methods
The clinical records of patients, ‡18 years of age, admitted
to seven Spanish hospitals with a diagnosis of CAP, requiring
hospitalization and parenteral treatment, who had been trea-
ted with ertapenem 1 g once a day, from July 2002 to June
2006, were retrospectively reviewed. Each ertapenem-trea-
ted patient was matched with two patients from the same
hospital treated with other parenteral antibiotics, except in
those cases where it was not possible to ﬁnd two matching
patients and only one was used. Matching criteria were: simi-
lar age (difference £5 years), same category Pneumonia
Severity Index (PSI) [16] and whether or not resident in a
nursing home. The study protocol was approved by the Ethi-
cal Review Board of Hospital Central de la Defensa
(Madrid).
Medical records were reviewed to obtain demographic,
clinical and analytical data, including those data necessary to
classify patients according to PSI category [16]. Data recorded
comprised: (i) demographic data: age, gender, nursing home
residence, previous antibiotic treatment; (ii) comorbidities:
malignancies, liver, renal, metabolic, endocrinological, heart or
vascular disease, chronic obstructive pulmonary disease; (iii)
clinical, radiological and analytical data for CAP diagnosis:
fever, cough, sputum characteristics, pleuritic chest pain, au-
scultatory ﬁndings, dyspnoea or tachypnoea, total peripheral
white blood cell count, PO2 or oxygen saturation by pulse
oximetry, chest radiograph; (iv) microbiological tests per-
formed; (v) initial antibiotic parenteral treatment and dura-
tion, and (vi) length of hospital stay and outcome.
Patients were excluded if they had received parenteral
antibiotic treatment for >24 h within the 72 h prior to hos-
pital admission and/or if they had a diagnosis of tuberculosis,
ventilator-associated pneumonia, nosocomial pneumonia,
shock, immunosuppression, cystic ﬁbrosis, neutropenia,
bronchiectasis, primary lung cancer or lung metastasis, men-
ingitis and/or HIV (<200 CD4/mm3).
Patients were assessed at the end of parenteral treatment
and until hospital discharge or death. Clinical response was
considered as resolution or improvement of baseline signs
or symptoms together with absence of progressive inﬁltra-
tion on chest X-ray. Clinical failure was deﬁned as: death,
persistence or worsening of baseline signs or symptoms,
emergence of new signs or symptoms, or requirement
of additional antibiotics different from those empirically
prescribed.
Comparison of proportions was performed by Chi square
test. Conﬁdence intervals of median values were used when
appropriate. Chi square for trends was used to compare
trends. Signiﬁcance level was established at p £0.05. The
Cochran–Mantel–Haenszel statistic was used to control for
variations between patient groups and the Breslow–Day test
was used to assess the homogeneity of the ORs.
Results
Seventy-one patients treated with ertapenem and 131
matched controls treated with other parenteral antibiotics,
complying with the inclusion criteria, were identiﬁed in the
study period. A total of 41 patients (20.3%) of the total pop-
ulation (202 patients) were receiving oral antibiotic treat-
ment on admission (12 with amoxicillin-clavulanate, ten with
macrolides, nine with quinolones, two with oral cephalospo-
rins and eight with antibiotic combinations).
A signiﬁcantly (p 0.0002) higher number of patients were
treated with monotherapy in the ertapenem group than in
the control group (other parenteral antibiotics) (83.1% vs.
57.2%). Of the 71 patients in the ertapenem group, 59
(83.1%) were treated with monotherapy while the 12
remaining patients were concomitantly treated with a macro-
lide (n = 8), a quinolone (n = 3) or ceftazidime (n = 1).
Among the 131 controls treated with other antibiotics, 75
(57.2%) patients were treated with monotherapy (31 with a
quinolone, 20 with a third-generation cephalosporin, 16 with
amoxicillin-clavulanate, ﬁve with piperacillin-tazobactam and
three with other antibiotics), and 56 with antibiotic combina-
tions (26 with b-lactam + quinolone combination, 19 with
b-lactam + macrolide combination, six with two b-lactams
and ﬁve with other combinations).
One hundred and twenty-nine patients (63.9%) were male:
60.6% and 65.6% for ertapenem and controls, respectively.
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Table 1 shows the matching criteria (age, residence in nurs-
ing homes and PSI) for the whole population and both treat-
ment groups. One hundred and seventy-four patients
(86.1%) belonged to classes IV–V of the severity score.
Three patients were treated in the intensive care unit. Six
patients were class II, and hospitalized because of comorbidi-
ties (diabetes, toxic hepatitis or previous lung resection).
Seventy-one of the 202 patients (35.1%) came from nurs-
ing homes. A signiﬁcantly (p <0.0001) higher PSI score was
found in patients coming from nursing homes (22.5% class IV
and 77.5% class V) than in those not institutionalized (23.4%
class II–III, 61.8% class IV and 16.8% class V).
The mean age of the study population was 80.5 ±
11.8 years, with 75% of patients over 76 years. One hundred
and ninety-three patients (95.5%) presented comorbidities,
which are shown for the whole population and both treat-
ment groups in Table 1. Cardiovascular (mainly hypertension,
congestive heart disease, ischaemia and ﬁbrillation) and neu-
rological (mainly dementia and stroke) disorders were
present in >50% of patients, metabolic disorders (mainly
diabetes) in 38.1%, respiratory disorders in 22.3%, urogenital
disorders (mainly renal impairment and prostatic disorders)
in 19.3% and gastrointestinal disorders (mainly ulcers) in
14.4%. Malignancies were present in 10.4% of the study
population.
Treatment duration, length of hospital stay, outcome and
mortality are shown in Table 2. The mean treatment dura-
tion was similar in both treatment groups (9.9 ± 4.3 days for
ertapenem and 10.1 ± 4.4 days for controls). No signiﬁcant
differences were found in median length of hospital stay
(7 days for ertapenem vs. 10 days for controls, p 0.066). The
clinical response was rather better for ertapenem treatment
than for other antibiotics (88.7% vs. 77.1%; p 0.0465; OR
2.25, 95% CI 0.99–5.12). Mortality during hospitalization was
4.5% (one patient out of 22) in PSI-III class (the patient suf-
fered amyotrophic lateral sclerosis), 4.1% (four out of 97) in
PSI-IV class, and 14.3% (11 out of 77) in PSI-V class, a signiﬁ-
cantly (p 0.028 Chi square for trends) higher mortality rate
than in classes PSI-III and PSI-IV. No differences in mortality
rates were found between treatment groups (8.5% for
ertapenem group vs. 7.6% for controls).
A poorer clinical response was obtained in those patients
coming from nursing homes than in those not institutional-
ized (74.6% vs. 84.7%), but differences did not reach statisti-
cal signiﬁcance (p 0.080). No difference (p 0.929) in clinical
response was found in non-institutionalized patients between
ertapenem (85.4% response rate) and control (84.5%) treat-
ments. On the other hand, in the subgroup of patients com-
ing from nursing homes the response rate with ertapenem
(95.8%) was signiﬁcantly higher than in controls (63.8%) (p
0.0034; OR 13.03, 95% CI 1.61–105.23).
Pre-therapy positive bacteriological cultures were obtained
from specimens from 29 patients (14.4%): 21 were respira-
tory samples and eight were blood cultures. Bacterial species
identiﬁed were S. pneumoniae in ten patients (six blood
cultures), Haemophilus inﬂuenzae in ten patients (one blood
culture), Escherichia coli in four patients (one blood culture),
Klebsiella pneumoniae in three patients, and Serratia marces-
cens and Moraxella catarrhalis in one patient each. In the
ertapenem group S. pneumoniae was isolated in six patients
(four of them with bacteraemia) and all patients showed a
clinical response. In the control group S. pneumoniae was iso-
lated in four patients (two of them with bacteraemia), and
two of them showed clinical failure (one with bacteraemia)
during treatment with levoﬂoxacin plus ceftriaxone. Nine of
the ten positive cultures for H. inﬂuenzae corresponded to
patients in the control group, with clinical response in all
patients with H. inﬂuenzae isolates except one patient in the
control group. The patient with a positive culture for Serratia
marcescens was treated with ertapenem and classiﬁed as clini-
cal failure after 11 days of monotherapy. Eight out of nine
Gram-negative bacilli were isolated in patients in the control
TABLE 1. Patient matching criteria (age, residence and PSI)
and comorbidities (%) present in more than 5% of the study
population
Total
(n = 202)
Ertapenem
(n = 71)
Controls
(n = 131)
Age (years, mean ± SD) 80.5 ± 11.8 80.2 ± 11.7 80.2 ± 11.9
Residence in nursing home n (%) 71 (35.1) 24 (33.8) 47 (35.9)
PSI-II n (%) 6 (3.0) 2 (2.8) 4 (3.1)
PSI-III n (%) 22 (10.9) 8 (11.3) 14 (10.7)
PSI-IV n (%) 97 (48.0) 34 (47.9) 63 (48.1)
PSI-V n (%) 77 (38.1) 27 (38.0) 50 (38.2)
Cardiovascular disorders 124 (61.4) 45 (63.4) 79 (60.3)
Neurological disorders 107 (53.0) 37 (52.1) 70 (53.4)
Metabolic disorders 77 (38.1) 28 (39.4) 49 (37.4)
Respiratory disorders 45 (22.3) 15 (21.1) 30 (22.9)
Urogenital disorders 39 (19.3) 15 (21.1) 24 (18.3)
Gastrointestinal 29 (14.4) 11 (15.5) 18 (13.7)
Cancer 21 (10.4) 10 (14.1) 11 (8.4)
Hepatic disorders 17 (8.4) 9 (12.7) 8 (6.1)
Haematological disorders 12 (5.9) 7 (9.9) 5 (3.8)
PSI, Pneumonia Severity Index.
TABLE 2. Treatment duration, hospital stay, outcome and
mortality
Ertapenem
(n = 71)
Controls
(n = 131)
Parenteral treatment duration
(days, mean ± SD)
9.9 ± 4.3 10.1 ± 4.4
Hospital stay, median days
(95% CI)
7 (4–10) 10 (6–13)
Clinical response, n (%) 63 (88.7) 101 (77.1)
Mortality, n (%) 6 (8.5) 10 (7.6)
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group, with four failures (three E. coli and one K. pneumo-
niae).
Positive urine pneumococcal antigen was identiﬁed in the
clinical records of 11 patients: three in the ertapenem group
(all of them with clinical response) and eight in the control
group (with one failure).
Discussion
In a previous pooled analysis of two clinical trials comparing
ertapenem with ceftriaxone [15], and showing equivalence,
around 50% patients belonged to PSI I–II class, 20–25% to
PSI III–IV class, with only 4% patients in the PSI-V class. In
addition, only 36% patients included could be considered
elderly (>65 years) and the mean age was 57 years. The er-
tapenem clinical response in elderly patients was similar to
that in the overall population regardless of the PSI score
[15,17].
To our knowledge, this is the ﬁrst study to assess the efﬁ-
cacy of ertapenem in the treatment of CAP in the uncon-
trolled setting of daily medical practice. The study was
retrospective (by reviewing clinical records of CAP patients
treated with ertapenem during 4 years just after licensure)
and included only seven Spanish hospitals, two facts that limit
the strength of the conclusions. However, it provides valu-
able data from daily practice about the potential of ertape-
nem in the treatment of hospitalized CAP patients. The
results of this study indicate that, at least in these centres,
ertapenem is administered in daily practice as treatment of
CAP-hospitalized patients mainly in the very elderly and
when patients present comorbidities. The study population
can be clearly considered a very old population (mean age
80.5 years; 91.6% patients >65 years, and 75% >76 years)
with the comorbidities associated with this aged setting (with
61.4% population with cardiovascular disorders, 53.0% with
neurological disorders, 38.1% with metabolic disorders and
10.4% with malignancies) and a severe pneumonia picture
(86.1% of patients classiﬁed as PSI IV–V). In this population
the clinical response with ertapenem was higher (p 0.0465)
than that obtained with pooled comparators used in clinical
practice (88.7% vs. 77.1%). This could inﬂuence length of
hospitalization, since hospital stay was shorter for ertapenem
(median values of 7 days for ertapenem vs. 10 days for com-
parators) although, since the difference did not reach statisti-
cal signiﬁcance (p 0.066), no deﬁnitive conclusions can be
drawn.
Moreover, 35.1% patients in the current study came from
nursing homes and thus can be considered patients with
healthcare-associated pneumonia (HCAP), a condition that
may be associated with multi-resistance, thus inﬂuencing
empirical treatment [7]. Patients with HCAP had more
severe pneumonia (as deﬁned by the PSI index) as previously
described [7]. In this subgroup of patients, ertapenem
showed signiﬁcantly higher clinical response than did the
antibiotics used as controls (95.8% vs. 63.8%; p 0.0034; OR
13.03, 95% CI 1.61–105.23). Although the higher clinical
response of ertapenem vs. comparators in the global popula-
tion was in the limit of signiﬁcance (p 0.0465), and this fact
together with the retrospective nature of the study suggest
that the results should be taken with caution, in the sub-
group of institutionalized patients with HCAP differences
favouring ertapenem were evident. This could be important,
because this subgroup of patients presented more severe
pneumonia (signiﬁcantly higher PSI score).
In addition to the retrospective nature of the study, a
potential criticism is the absence of Legionella coverage by
the ertapenem treatment of severe pneumonia. In a country
such as Spain where Legionella outbreaks or sporadic cases
are kept in mind by the physicians when managing severe
pneumonia, testing for Legionella antigen in urine is widely
used, and if the possibility of this aetiology cannot be
excluded, appropriate coverage with a macrolide can be pro-
vided.
In summary, the results of this retrospective study analy-
sing data from daily practice suggest that ertapenem adminis-
tered as 1 g once a day was equivalent to comparator for
non-institutionalized severe CAP in elderly patients (where
CAP incidence is much higher than the 2–10 cases per 1000
inhabitants described for the general population) [5,18] with
associated comorbidities, but showed signiﬁcant superiority
in the more severe CAP in patients from nursing homes.
These results obtained in daily practice indicate the adequacy
of ertapenem monotherapy (once Legionella has been
excluded) as hospital treatment of severe HCAP in institu-
tionalized patients.
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